期刊文献+

化疗药物诱导的手足综合症 被引量:8

Hand-foot syndrome induced by chemotherapy drugs
下载PDF
导出
摘要 手足综合症(HFS)通常是由化疗药物诱导的一种皮肤毒性反应,许多化疗药物在不同程度上表现出这一不良反应。本综述介绍了HFS的临床表现、毒性分级、导致这一症状的常见化疗药物及其可能的病因、预防与治疗措施等。 Hand-foot syndrome is a cutaneous toxic reaction that is often induced by chemotherapy drugs, many chemotherapy drugs have been reported to cause the condition to the different degree. This review introduces clinical manifestation, toxic classification,frequent chemotherapy drugs, pathogenesis, preventive and treatment measures for HFS.
出处 《中国临床药理学与治疗学》 CAS CSCD 2009年第2期210-213,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 上海市科委纳米专项(0652nm016 0752nm021)
关键词 手足综合症 化疗药物 皮肤毒性 hand-foot syndrome chemotherapy drugs cutaneous toxicity
  • 相关文献

参考文献26

  • 1Nagore E, Insa A, Sanmartin O. Antineoplastic therapyinduced palmar plantar erythrodysesthesia ('hand-foot') syndrome, incidence, recognition and management [ J ]. Am J Clin Dermatol, 2000,1(4) :225 - 234.
  • 2Zuehlke RK. Erythematous eruption of the palms and soles associated with mitotane therapy [ J ]. Dermatologica, 1974,148(2) :90 - 92.
  • 3Wilkes GM, Doyle D. Palmar-plantar erythrodysesthesia [J]. J Oncol Pharm Practice, 2003,9(4): 137- 150.
  • 4Hellier I, Bessis D, Sotto A, et al. High-dose methotrexate-induced bullous variant of acral erythema[J]. Arch Dermatol, 1996,132(5) :590 - 591.
  • 5Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol, 1999,17(2):485- 493.
  • 6Lorusso D, Stefano A Di, Carone V, et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome) [J]. Ann Onc, 2007, 18(7): 1159 - 1164.
  • 7Tardi PG, Boman NL, Cullis PR. Liposomal Doxorubicin [J]. J Drug Target, 1996,4(3) : 129- 140.
  • 8Gordon KB, Tajuddin A, Guitart J, et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy[J]. Cancer, 1995,75(8):2169- 2173.
  • 9Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractarory ovarian cancer: antiturnor activity and toxicity modification by liposornal encapsttlation[J]. J Clin Oncol, 1997,15 (3) : 987 - 993.
  • 10Uziely B, Jeffers S, Isacson R, et al. Liposomal doxombicin: antitumor activity and unique toxicities during two complementary phase l studies[J]. J Clin Oncol, 1995,13 (7) : 1777 - 1785.

共引文献366

同被引文献51

引证文献8

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部